Abstract
BACKGROUND
Hispanics are the largest minority group in the U.S. Most studies assessing race as a predictor of biochemical disease recurrence after radical retropubic prostatectomy (RRP) have focused on African‐American patients. To the authors' knowledge, little has been published to date regarding radical prostatectomy in Hispanic patients. Hispanics represent 29% of the patients in the current study. The authors analyzed the presentation and outcome of Hispanic males managed with radical prostatectomy.
METHODS
In the current study, 1163 RRPs were performed. Patients were categorized by ethnicity as Hispanics, white non‐Hispanics, African‐Americans, and other ethnicities. African‐American and other minority group patients were excluded from the analysis because of the small number in the current series. A comparative analysis of Hispanics and white non‐Hispanics was performed.
RESULTS
RRP was performed in 1163 patients. Two hundred seven Hispanic and 518 white non‐Hispanic patients met the study criteria. The mean follow‐up was 46.9 months. Twenty‐three percent of the Hispanic patients received neoadjuvant therapy. RRP Gleason scores of 2–6, 7, and 8–10 were found in 45% of patients, 38% of patients, and in 17% of patients, respectively. Lymph node metastases were present in 3%, seminal vesicle invasion in 13%, and extraprostatic extension in 23% of Hispanic patients. Adjuvant hormonal therapy was administered to 6% of the Hispanic patients. The biochemical disease recurrence rate was 12%. The mean time to biochemical disease recurrence was 29.7 months. A comparison between the Hispanic and the white non‐Hispanic groups showed no significant differences in the analyzed variables.
CONCLUSIONS
Hispanic patients managed with radical prostatectomy for prostate carcinoma were found to have similar presentation, pathologic findings, and outcome as the white non‐Hispanic patients. Cancer 2004. © 2004 American Cancer Society.